Steve Mattmuller, MS, RPh, BCNP

Steve Mattmuller was 13 when he started his career in the pharmacy profession as a stock boy at his dad’s pharmacy in Aurora, Ohio.

He graduated from the USC Radiopharmacy program in 1980, his first position was at St. John’s Mercy Medical Center in St. Louis, Missouri. St. John’s is a community hospital with a comprehensive NM department that provided a challenging environment.

In 1995 he returned to his native Ohio to Kettering Medical Center where he still practices. Kettering likewise is a community hospital with a comprehensive NM/PET department. It is yet another challenging environment, especially with a cyclotron.

It was during his time at Kettering he became active in APhA’s SIG on Nuclear Pharmacy serving on various committees and as chair of the SIG in 2009. He also served on various committees with the SNMMI and on two expert advisory committees for the USP on PET and <823>.

In 2008 he served for eight years on the NRC ACMUI committee, serving on several sub-committees. He chaired the sub-committee on Ga-68 Generators, Regulatory Exemption for Decommissioning Funding Plan (DFP). It’s focus was a NRC regulation that triggered an expensive DFP requirement that would restrict the use of Ga-68 generators in the NM field. The sub-committee was successful in getting an exemption that resulted in relief from an onerous NRC regulation.

In 2015 he served for six years on the DOE, NNSA, Nuclear Science Advisory Committee’s sub-committee on Mo-99. The DOE’s program’s goal was to develop a domestic source of Mo-99 production without the use of highly enriched uranium. The sub-committee’s task was to review the DOE’s funded research at National Laboratories and the DOE’s cooperative agreements that helped fund new Mo-99 producers.

He also served on the board for the Coalition of PET Drug Manufacturers and continues to serve the BPS.